Biomarck Pharmaceuticals, Ltd announced that statistical significance (p=0.02) was achieved in improvement of Overall Response Rate (ORR) in the BIO-11006/SOC group compared to standard of care alone at 3 months in the Phase II study in NSCLC. 
 
BIO-11006/SOC also showed less Disease Progression (DP) than SOC alone (7% to 17% respectively) and more Partial Response (PR) than SOC (40% to 30%).
 
BIO-11006 was well tolerated with cough, dyspnea and headache being most commonly (5%) related adverse events. BIO-11006 has, in Invitro studies, shown activity against all solid tumors tested including lung, breast, colon and sarcoma. It is part of a portfolio of over 100 patented compounds owned by Biomarck.